Loading clinical trials...
Loading clinical trials...
A Phase 1, Two-Part, Open-Label Study to Assess the Relative Bioavailability of Two TD-1473 Tablet Formulations Under Fasted and Fed Conditions in Healthy Subjects and the Pharmacokinetics of TD-1473 in Healthy Chinese Subjects
Conditions
Interventions
TD-1473 [Tablet A]
TD-1473 [Tablet B]
Locations
2
United States
Theravance Biopharma Investigational Site
Cypress, California, United States
Theravance Biopharma Investigational Site
Lincoln, Nebraska, United States
Start Date
October 16, 2020
Primary Completion Date
December 24, 2020
Completion Date
December 27, 2020
Last Updated
April 9, 2021
NCT07355777
NCT06573723
NCT07257835
NCT03823742
NCT06309199
NCT05132816
Lead Sponsor
Theravance Biopharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions